人类白细胞抗原
杂合子丢失
免疫学
免疫疗法
生物
CD8型
免疫检查点
基因型
癌症研究
癌症免疫疗法
生殖系
抗原
免疫系统
基因
等位基因
遗传学
作者
Diego Chowell,Luc G.T. Morris,Claud M. Grigg,Jeffrey K. Weber,Robert M. Samstein,Vladimir Makarov,Fengshen Kuo,Sviatoslav M. Kendall,David Requena,Nadeem Riaz,Benjamin D. Greenbaum,James Carroll,Edward B. Garon,David Michael Hyman,Ahmet Zehir,David B. Solit,Michael F. Berger,Ruhong Zhou,Naiyer A. Rizvi,Timothy An-thy Chan
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2017-12-07
卷期号:359 (6375): 582-587
被引量:1260
标识
DOI:10.1126/science.aao4572
摘要
HLA genotype affects response Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516
科研通智能强力驱动
Strongly Powered by AbleSci AI